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Abstract
G-protein coupled receptors (GPCRs) are widely expressed cell surface receptors that have been
successfully exploited for the treatment of a variety of human diseases. Recent studies in genetically
engineered mouse models have led to the identification of several GPCRs important for lymphatic
vascular development and function. The adrenomedullin receptor, which consists of an oligomer
between calcitonin receptor-like receptor and receptor activity modifying protein 2, is required for
normal lymphatic vascular development and regulates lymphatic capillary permeability in mice.
Numerous studies also suggest that lysophospholipid receptors are involved in the development of
lymphatic vessels and lymphatic endothelial cell permeability. Given our current lack of
pharmacological targets for the treatment of lymphatic vascular diseases like lymphedema, the
continued identification and study of GPCRs in lymphatic endothelial cells may eventually lead to
major breakthroughs and new pharmacological strategies for the treatment of lymphedema.
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G-protein coupled receptors as drug targets
G-protein coupled receptors (GPCRs) are widely expressed proteins that span the cell
membrane 7 times and respond to a variety of stimuli including peptides, proteins, small
organic compounds, lipids, amino acids and cations. Recent estimates predict that humans have
approximately 800 GPCRs which can be grouped into five major phylogenetic families:
Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2 families.1 A comprehensive
review article exploring the diversity between GPCR families and its significance for drug
design was recently published by Lagerstrom & Schioth.2 In summary, GPCRs from every
family are highly attractive targets for pharmacological manipulation by either recombinant
proteins, small molecule compounds, allosteric ligands or antibodies. There are currently 46
GPCRs that serve as drug targets for the treatment of a multitude of conditions including
hypertension, pain, ulcers, allergies, alcoholism, obesity, glaucoma, psychotic disorders and
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HIV. However, this leaves several hundreds of GPCRs as potential drug targets and among
those approximately 150 are still considered orphan receptors (receptors for which the
endogenous ligand has yet to be identified).2 One major impediment to increasing the repertoire
of pharmacologically useful GPCRs is our general lack of knowledge regarding the association
of a putative GPCR with a precise physiological function or disease condition. Therefore, as
scientists embark on the journey of elucidating the pathophysiology of complex and poorly
treatable diseases, one beneficial approach may be to identify GPCRs associated with the
condition, because they may eventually translate into effective drug targets.
Diseases of the lymphatic vascular system and current therapies
Diseases of the lymphatic vascular system serve as an example of how lack of knowledge about
normal and diseased tissues has limited our ability to generate many effective pharmacological
therapies. The lymphatic vascular system normally works to maintain tissue fluid homeostasis,
absorb fatty acids and lipid-soluble vitamins from the gut and traffic antigen-presenting
immune cells through the lymph nodes. Therefore, failure of the lymphatic vascular system
has devastating consequences.3 Lymphedema is the result of inadequate lymphatic function
and if not properly managed can lead to debilitating and painful limb swelling, tissue fibrosis,
inflammation and increased susceptibility to infection. Lymphedema can be caused by rare
genetically-inherited mutations resulting in abnormal development or function of the lymphatic
vascular system either at birth, puberty or adulthood.4 More common causes of lymphedema
are due to physical disruption or damage to the lymphatic vasculature, either by surgery,
radiation therapy or infection with the mosquito parasites Wuchereria bancrofti or Brugia
malayi. In industrialized countries, the occurrence of lymphedema is rapidly increasing,
proportional to the increasing use of surgical and radiation therapies for life-saving cancer
treatments. Recent estimates show that one third to nearly one half of women develop
lymphedema after breast cancer treatments.5, 6 In many tropical and sub-tropical countries,
parasitic filarial lymphedema or elephantiasis is endemic and affects approximately 120 million
individuals worldwide.7 Regardless of the cause, lymphedema carries with it immense
psychological and social sequelae and disability.3
Rockson has recently provided a survey of current treatment strategies for the management of
lymphatic vascaular disease.8 Currently, the most effective treatment for lymphedema consists
of a multifaceted physiotherapeutic approach for improving lymphatic function through
application of lymphatic-specific massage techniques, remedial exercise, fitted compression
garments and skin care.8 Although this all-inclusive approach is largely successful among
compliant patients9, the daily treatments and changes in lifestyle can cause undesirable
financial, physical and psychological strain for many patients.
Recent surgical approaches have provided limited relief to patients with severe lymphedema.
For example, liposuction followed by sustained intense compression can relieve tissue
congestion caused by collagen and fat deposition.10, 11 However, liposuction only provides
temporary relief from swelling and does not directly improve lymphatic function.
Reconstructive microsurgery through lymphavenous anastomoses (in effect, lymphatic bypass
surgery) can provide minimal relief but is largely ineffective.12
Pharmacological therapies for lymphedema are extremely limited and largely controversial.
Coumarin has been shown to reduce lymphedema, but its overall effectiveness and functional
mechanism remain controversial.13-15 Moreover, long term systemic treatment with coumarin
is correlated with a high rate of hepatotoxicity.13, 16 Antioxidents, including selenium and
flavonoids, have also been explored as potential therapies, but preliminary investigations into
their effectiveness have remained inconclusive.17 The treatment for parasitic filarial
lymphedema has had better success. Massive drug delivery programs, consisting of dual
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treatment with diethylcarbamazine and albendazole (anti-parasitic agents), can effectively
target and eliminate infecting parasites and reduce the burden of filarial lymphedema in large
populations.18 However, treatment strategies for filariasis do not repair the previously damaged
lymphatic vasculature within an individual.
Perhaps the most exciting progress toward pharmacological treatments for lymphedema has
come from vascular endothelial growth factor C (VEGFC)-based therapies. As described
below, VEGFC is a potent growth and migratory factor for lymphatic endothelial cells. In
animal models of lymphedema, VEGFC-based therapies have been demonstrated to promote
lymphangiogenesis.19-23 Even more promising has been the recent discovery that adenovirally-
delivered VEGFC can induce the formation of functional collecting lymphatics as well as
improve the outcomes of lymph node transplantations in mice.22 Other growth factors,
including VEGFD, VEGFA, fibroblast growth factor-2 and hepatocyte growth factor have also
shown exciting promise as therapeutic lymphangiogenic agents in animal models.24, 25
Nevertheless, it remains clear that the identification of additional drug targets for the
modulation of lymphatic growth or permeability is highly desirable. Because GPCRs are
pharmacologically-tractable cell-surface receptors and are widely used for the treatment of
human diseases, the identification of potentially useful GPCR targets for the modulation of
lymphatic vascular growth or function would represent a major advancement in the field. In
the following sections, we highlight recent discoveries from animal models that have
uncovered novel roles for several GPCRs in lymphatic vascular development and function.
Lessons in lymphangiogenesis from gene knockout models
In the past 10 years, phenotypic characterization of gene knockout mouse models has resulted
in remarkable progress toward identifying genes important in the development and function
of the lymphatic vascular system. The impact that gene targeting has had on driving the field
forward is unparalleled, and so it is fitting that the 2007 Nobel Prize in Physiology or Medicine
was awarded to Smithies, Capecchi and Evans in recognition of their efforts toward developing
gene targeting approaches. Several elegant and fully comprehensive reviews have recently
been published with in depth details and insights on how the phenotypes of gene targeted animal
models have built the foundation for understanding lymphangiogenesis.26-28
Figure 1 summarizes our current understanding of the stepwise process of lymphangiogenesis
and lists numerous genetic factors that have been identified as important for lymphangiogenesis
through gene targeting approaches. Development of the lymphatic vascular system is initiated
when lymphatic-endothelial-hyaluronan-receptor-1 (LYVE1)-expressing endothelial cells of
the cardinal vein begin to express the transcription factor sex determining region Y-box 18
(Sox18) which drives expression of prospero-related homeobox 1 (Prox1) in a polarized
manner.29 Sox18 and Prox1 transcriptionally reprogram venous endothelial cells so that they
become specified toward a lymphatic fate.29, 30 The up-regulation of the VEGFC receptor,
VEGFR3, in lymphatic endothelial cells confers their ability to sprout from the cardinal vein
and migrate toward an ectopic gradient of growth-promoting VEGFC.31 The lymphatic
endothelial cells organize into primary lymph sacs which eventually separate from the cardinal
vein in a process dependent on several genes, including tyrosine kinase Syk and adaptor protein
Slp76, phospholipase C gamma 2 (Plcγ2) and sprouty-related, EVH1 domain 1 and 2
(Spred1&2).32-34 Subsequent rounds of proliferation lead to the formation of a primary
lymphatic plexus which is later remodeled with mural cells and luminal valves to form the
fully functional lymphatic vascular network.
Progress toward elucidating these developmental steps has been steadfast over the past 10
years, with a handful of new genetic players identified every year. But only recently have
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GPCRs become implicated in lymphangiogenesis and the following sections highlight these
new discoveries with an emphasis on how these receptors may be pharmacologically beneficial.
Calcitonin receptor-like receptor
The calcitonin receptor-like receptor (CALCRL) belongs to the Secretin family of GPCRs; a
small family of 15 receptors that bind peptide hormones and have extended extracellular N’
terminal hormone-binding domains.2 A distinguishing feature of several Secretin family
receptors is their ability to associate with single-pass transmembrane proteins that can alter
receptor trafficking, ligand binding and downstream signaling.35 The identification and
characterization of these 3 mammalian receptor activity modifying proteins (RAMP1−3) was
first established with CALCRL, such that RAMP1 association with CALCRL produces a
receptor with high affinity for calcitonin gene-related peptide (CGRP) whereas association
with RAMP2 or RAMP3 produces a receptor with preferential binding to adrenomedullin
(AM).36 Recently, a third endogenous peptide ligand, intermedin, was also shown to signal
through CALCRL-RAMP complexes.37 Therefore, whether a cell to responds to either CGRP,
AM or intermedin is largely dependent on the extent of RAMP expression. The unique ability
of RAMPs to modulate receptor ligand binding properties has already been exploited in drug
design. Two small molecule compounds that antagonize CGRP binding to the CALCRL-
RAMP1 oligomer are currently in clinical trials for the management of pain associated with
migraine.38 Although no compounds have yet been described for CALCLR-RAMP2
oligomers, our recent studies in genetically engineered mouse models suggest that CALCRL-
RAMP2 oligomers may represent ideal drug targets for the lymphatic vasculature.
Several years ago, our laboratory began to systematically generate and comparatively
phenotype gene knockout mice for all mammalian RAMPs, CALCRL and AM with the hopes
of identifying conserved (or divergent) phenotypes in which the use of RAMP-based
compounds could be beneficial for the treatment of human diseases.39-42 The most striking of
phenotypes, embryonic lethality at mid-gestation, occurs in knockout mice for AM, CALCRL
and RAMP2.42 Remarkably, each of these knockout mice shares a highly conserved appearance
of generalized edema without hemorrhage, which not only provides compelling evidence that
AM-CALCRL-RAMP2 constitutes a physiologically relevant signaling pathway but also
suggests that the development of the lymphatic vascular system is abnormal. Indeed, the AM,
CALCRL and RAMP2 knockout mice all suffer from substantially smaller jugular lymphatic
vessels due to significantly reduced proliferation of lymphatic endothelial cells compared to
venous endothelial cells during mid-gestation.42 Elegant studies by Jin and colleagues also
show that AM-treatment of adult mice with tail lymphedema significantly improves
lymphedema and promotes in vivo lymphangiogenesis.43
Although several studies demonstrate that AM can affect the proliferation, permeability and
growth of the blood vasculature44, 45, the prevalence of the lymphatic vascular defects in the
knockout models is supported by numerous other studies. For example, comparative gene
profiling studies between blood endothelial cells (BECs) and lymphatic endothelial cells
(LECs) consistently demonstrate that CALCLR and RAMP2 are preferentially up-regulated
in the lymphatic lineage.46, 47 While some of this up-regulation can be attributed to
transcriptional regulation by the lymphatic-specific transcription factor Prox142, recent studies
also suggest that down-regulation of RAMP2 levels by a blood-enriched microRNA may
equally contribute to the enhanced expression of RAMP2 in LECs (personal communication,
Dr. Michael Detmar, Univ. Zurich, Switzerland). Comparative gene profiling experiments also
reveal that Complement Factor H, the serum binding protein for AM that enhances AM peptide
activity by 2-fold48, is significantly enriched in LEC compared to BECs.49 Finally, mice with
genetic deletion of the enzyme required for functionally activating AM peptide through
amidation, peptidylglycine alpha-amidating monooxygenase (PAM), precisely phenocopy the
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AM, CALCRL and RAMP2 knockout mice50; though in depth characterization of the
lymphatic vasculature has not yet been performed. Taken together, these studies demonstrate
that several mechanisms are in place to ensure that the local bioactivity of AM peptide and the
sensitivity to CALCRL-RAMP2 signaling are highly enriched in the lymphatic vasculature.
This is further supported by our recent study demonstrating that the principal effect of
subcutaneous AM peptide injection is to significantly decrease local lymphatic permeability
in the dermal lymphatic vessels of the mouse tail.51 So, although the broad tissue distribution
of CALCRL-RAMP2 may cause some hesitation for drug design (due to undesirable off-target
side effects), the inherent sensitivity and up-regulation of AM receptors in the lymphatic
endothelium may prove to be highly beneficial.
Lysophospholipid receptors
Lysophospholipid (LP) receptors belong to the Rhodopsin family of GPCRs and bind bioactive
lipids to elicit a wide range of cellular effects. Originally known as endothelial differentiation
gene receptors (Edg), these receptors are currently designated as either lysophosphatidic acid
receptors (LPA1−3) or sphingosine-1-phosphate receptors (S1P1−5), reflective of their
respective lipid ligands.52 LP receptors are nearly ubiquitously expressed and cells may express
multiple subtypes.53 The bioactive lipid ligands LPA and S1P are also widely expressed but
most highly produced by platelets, which when activated release LPA and S1P into the
bloodstream in the micromolar range.54, 55 LP receptor signaling has been shown mediate
angiogenesis, permeability, vascular tone, and cardiac function56-59 as well as participate in
the immune response through regulation of lymphocyte trafficking.60-63 Currently, several
preclinical and clinical stage studies are being undertaken, utilizing both antagonist and agonist
of LP receptors, in the hopes of providing therapies against tumor growth and
metastasis64-66 and autoimmune disorders including multiple sclerosis, kidney graft rejection,
and inflammation.67-71
Recent genetic studies in zebrafish have demonstrated an essential role for LPA signaling in
lymphatic vascular development since morpholino-based knockdown of zebrafish LPA
(zlpa1) resulted in failure of thoracic duct development.72 Interestingly, this phenotype was
partially rescued by VEGFC over-expression, suggesting that LPA and VEGFC signaling may
converge to promote lymphatic vessel development.72 In another study, ligand binding to
LPA1/3 receptors on human umbilical venous endothelial cells (HUVECs) increased VEGFC
expression and secretion.73, 74 Remarkably, LPA stimulation also promoted the formation of
Prox1 and podoplanin positive capillary tubes, suggesting that LPA signaling has the ability
to confer lymphatic identity.74 Many studies demonstrate that LPA can modulate the
paracellular permeability of the endothelial cell barrier.59 Although there are no reports
specifically describing LPA-mediated effects on LEC permeability, the broad effects of LPA
on endothelial cell function make it likely that LPA also affects LEC permeability. Gene
targeted knockout mouse models of LPA1, LPA2, and LPA3 receptors do not display any
cardiovascular developmental defects.75-77 However, mice null for autotaxin (ATX), the
enzyme necessary for producing bioactive LPA, are embryonic lethal with severe vascular
defects, suggesting that the LPA(1−3) receptors may be functionally redundant in the
developing vasculature.78 Given the recent evidence that LPA functions as a potent
lymphangiogenic factor, extensive re-evaluation of the LPA(1−3) null mice for lymphatic
vascular defects may be informative.
Sphingosine-1-phosphate activation of S1P1/3 receptors in LECs also promotes
lymphangiogenesis both in vitro and in vivo.79 Compared to HUVECs, LECs expressed more
S1P1/3 receptors and following stimulation with S1P, secreted more angiopoeitin-2, a potent
lymphangiogenic factor.80 Several studies have demonstrated that S1P signaling decreases
endothelial cell permeability through reorganization of junctional proteins at the plasma
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membrane.58, 81 Recent studies exploring lymphocyte trafficking into the lymphatic sinuses
showed that S1P1 stimulation effectively tightened the lymphatic endothelial cell barrier and
these effects may be due to enhanced organization of junctional components including ZO-1,
CD31, and β-catenin.63, 65, 82 The predominant phenotype of the S1P1 knockout mice is
massive hemorrhage at mid-gestation caused by an endothelial-specific failure in vascular
smooth muscle cell recruitment and vessel maturation.83, 84 Mice lacking all three S1P
receptors (S1P1, S1P2, and S1P3) had exacerbated vascular deficiencies compared to S1P1
knockout mice, while S1P2-S1P3 double knockout mice exhibited partial lethality with fragile
endothelial cells prone to hemorrhage.85 These data suggest that S1P receptors have both
redundant and cooperative functions during vascular development, but do not preclude the
possibility that S1P signaling may play an important role in lymphatic vascular development
or function.
Taken together, an increasing number of new studies, both in vivo and in vitro, suggest that
lysophospholipid receptors may mediate important biological functions in the lymphatic
vasculature, including lymphangiogenesis, vessel integrity, LEC permeability and potential
cross-talk with other lymphangiogenic factors. Since LP receptors are already being
pharmacologically exploited for the treatment of human disease, future studies focused on the
effects of lysophospholipids on the lymphatic vasculature may lead to new GPCR targets for
the modulation of lymphatic growth or function.
Searching for other GPCRs in lymphatic endothelial cells
Because GPCR proteins are typically expressed at low levels in endogenous tissues, the use of
proteomic profiling approaches for identifying lymphatic-specific GPCRs may prove
problematic. Also, since antibodies directed against the extracellular domain of GPCRs can be
difficult to generate and/or lack specificity, the use of immunohistochemical approaches to
identify lymphatic-specific GPCRs may also provide limited benefit. So, perhaps the best
approach lies in genome-wide transcriptional profiling approaches, where cohorts of genes that
are differentially expressed between LECs and BECs can be identified and compared.
Fortunately, several research groups have already performed these very informative and
elegant experiments.46, 47, 49 In all of these studies, there exist at least 6 GPCRs that appear
to be enriched in LECs, and most of them are still considered orphan receptors with no identified
ligand. The importance of GPCR signaling in LECs is also supported by the increased
expression in LECs of several GPCR signaling modifiers, like regulator of G-protein signaling
2 (RGS-2), RGS-16 and β-arrestin.47, 49
Olfactory receptors are the largest class of GPCRs, with 388 predicted human receptors, and
belong to the Rhodopsin receptor family. Nearly all are considered orphan receptors, and
beyond the fragrance industry they have not generally been considered as candidate drug targets
for human diseases.2 However, it is interesting to recognize that like the CALCRL-RAMP
paradigm, several olfactory receptors have been associated with RAMP-like accessory
proteins, called receptor accessory proteins (REEPs).86 Like RAMPs, REEPs can promote the
surface expression of olfactory receptors and modulate their function.86, 87 Interestingly, the
Petrova et al study showed that REEP1 was overexpressed 2.5-fold more in LECs than in BECs.
47 The broad tissue distribution of olfactory receptors beyond the olfactory epithelium suggests
they may have other functions beyond smell. In fact, olfactory receptors have recently been
implicated in kidney function and sperm chemotaxis.88, 89 Although openly speculative, it is
intriguing to consider that olfactory receptors enriched in lymphatic endothelium might serve
as chemosensory factors for mediating developmental lymphangiogenesis or for sensing
changes in interstitial fluid composition. Of course, future experiments using genetic
engineering approaches in mice need to be undertaken to fully explore this hypothesis.
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In conclusion, recent studies in genetically engineered mouse models have led to the
identification of several GPCRs important for lymphatic vascular development and function.
Given our current lack of pharmacological targets for the treatment of lymphatic vascular
diseases like lymphedema, the continued identification and study of GPCRs in lymphatic
endothelial cells may eventually lead to major breakthroughs and new pharmacological
strategies for the treatment of lymphedema.
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Figure 1. Stepwise process of lymphangiogenesis
The development of the lymphatic vasculature begins with specification of lymphatic
endothelial cells from venous precursors. The chemoattractant and growth promoting
properties of numerous growth factors, including VEGFC, causes lymphatic endothelial cells
to sprout and separate from veins to form primitive lymph sacs. Proliferation of lymph sacs
leads to the formation of a primary lymphatic plexus which is later remodeled into the mature
lymphatic vascular system. Below each step is a list of genes for which a functional role has
been demonstrated using genetically engineered mouse models.
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Figure 2. Newly identified GPCRs involved in lymphatic development and function
Several recent studies have led to the identification of several GPCR signaling paradigms that
are required for lymphatic vascular development and function. The receptor complex for
adrenomedullin (AM) peptide consists of calcitonin receptor-like receptor (CALCRL) and
receptor activity modifying protein 2 (RAMP2). Together, these proteins regulate the
proliferation and permeability of lymphatic endothelial cells. The lysophospholipids
lysophosphatidic acid (LPA1) and sphingosine-1-phosphate (S1P) signal through their cognate
GPCRs, LPA(1−5) and S1P(1−3). Numerous studies demonstrate that lysophospholipid
signaling can regulate lymphatic endothelial cell differentiation, proliferation and
permeability.
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